Specialty Pharma Journal Specialty, Precision & Technology
SOUTH PLAINFIELD, N.J., July 19, 2018 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into an agreement to acquire Agilis Biotherapeutics, Inc., a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system (CNS). The transaction was approved by the Boards of …
Tag Archives: CNS
July, 2018
June, 2018
-
11 June
Alexion and Complement Pharma Partner to Develop Complement Inhibitor for Neurodegenerative Disorders
NEW HAVEN, Conn., & AMSTERDAM–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Complement Pharma today announced a partnership to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. C6 inhibition prevents the formation of the destructive membrane attack complex (MAC), a complex of terminal complement proteins that mediate cellular injury following …
November, 2017
-
10 November
Sanofi Signs License Deal with Principia Biopharma for Multiple Sclerosis Drug Candidate
Paris, France and South San Francisco, Calif – November 9, 2017 – Sanofi will develop Principia Biopharma Inc.’s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases. Under the license agreement signed this week, Sanofi will develop Principia’s Bruton’s tyrosine kinase (BTK) …
September, 2017
-
29 September
Zogenix’s Treatment for Dravet Syndrome Demonstrates Positive Results in Late-Stage Study
EMERYVILLE, Calif., Sept. 29, 2017 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today reported positive top-line results from its first Phase 3 trial (Study 1) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of Dravet syndrome. The …
May, 2017
-
26 May
Merck Enters License Agreement with Teijin Pharma for its Anti-Tau Alzheimer’s Candidate
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has entered into an exclusive worldwide license agreement with Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical antibody candidate targeting the protein tau. Changes in tau are associated …
April, 2017
-
26 April
New Data from Genzyme’s Phase 3 Study Suggest Positive Effects of Aubagio on Cortical Gray Matter Atrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that new investigational data evaluating the effect of Aubagio® (teriflunomide) on cortical gray matter atrophy in patients with a first clinical episode suggestive of MS will be presented at the 69th American Academy of Neurology (AAN) …
August, 2016
-
2 August
Pfizer Acquires Gene Therapy Company Bamboo Therapeutics
Pfizer Inc. (NYSE:PFE) today announced that it has acquired Bamboo Therapeutics, Inc., a privately held biotechnology company based in Chapel Hill, N.C., focused on developing gene therapies for the potential treatment of patients with certain rare diseases related to neuromuscular conditions and those affecting the central nervous system. This acquisition …
July, 2016
-
20 July
An Antibody-Based Drug for Multiple Sclerosis
Inserm Unit U919, directed by Prof. Denis Vivien (“Serine Proteases and Physiopathology of the Neurovascular Unit”) has developed an antibody with potential therapeutic effects against multiple sclerosis. The study, directed by Fabian Docagne and published in Brain, paves the way for a new strategy to control the disease. Multiple sclerosis …
May, 2016
-
16 May
Biogen Collaborates with University of Pennsylvania to Advance Gene Therapy and Gene Editing Technologies
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ:BIIB) today announced a broad collaboration and alliance with the University of Pennsylvania (“Penn”) to advance gene therapy and gene editing technologies. The expansive research and translational development collaboration has multiple objectives, but will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system …
January, 2016
-
25 January
Alkermes Initiates Clinical Testing of its Alzheimer’s Disease Drug Candidate
DUBLIN–(BUSINESS WIRE)–Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of ALKS 7119, an oral, investigational drug candidate being developed for the treatment of agitation in patients with Alzheimer’s disease (AD) and other central nervous system (CNS) indications. The double-blind, placebo-controlled study will evaluate the …